James Willhite was an editor with The Wall Street Journal's money & investing team based in London.

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in ...

Novavax is working closely with federal drug regulators to get full approval for its COVID shot. The vaccine is the only ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA ...

Measles is caused by a highly contagious virus that’s airborne and spreads easily when an infected person breathes, sneezes ...

Researchers have uncovered a critical, previously underappreciated role for B cells in vaccine protection. Best known for producing antibodies, B cells also guide other immune cells, specifically CD8 ...

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...

While measles immunity lasts a lifetime, some people who received only one shot or an older version of the vaccine may ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

The timing and type of measles vaccine you received in childhood can influence whether a booster shot is necessary.